These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8912540)

  • 1. Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells.
    Tagliabue E; Ardini E; Pellegrini R; Campiglio M; Bufalino R; Jeschke M; Groner B; Colnaghi MI; Ménard S
    Br J Cancer; 1996 Nov; 74(9):1427-33. PubMed ID: 8912540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells.
    Campiglio M; Tagliabue E; Srinivas U; Pellegrini R; Martignone S; Ménard S; Colnaghi MI; Lombardi L; Marchisio PC
    J Cell Biochem; 1994 Aug; 55(4):409-18. PubMed ID: 7962174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.
    Pupa SM; Ménard S; Andreola S; Colnaghi MI
    Cancer Res; 1993 Dec; 53(24):5864-6. PubMed ID: 7903196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.
    Giani C; Casalini P; Pupa SM; De Vecchi R; Ardini E; Colnaghi MI; Giordano A; Ménard S
    Oncogene; 1998 Jul; 17(4):425-32. PubMed ID: 9696035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
    Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
    Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells.
    Tagliabue E; Ghirelli C; Squicciarini P; Aiello P; Colnaghi MI; Ménard S
    Clin Cancer Res; 1998 Feb; 4(2):407-10. PubMed ID: 9516929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
    Looi LM; Cheah PL
    Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.
    Lewis GD; Figari I; Fendly B; Wong WL; Carter P; Gorman C; Shepard HM
    Cancer Immunol Immunother; 1993 Sep; 37(4):255-63. PubMed ID: 8102322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p185HER2 overexpression in human breast cancer using molecular and immunohistochemical methods.
    Johnson RC; Ricci A; Cartun RW; Ackroyd R; Tsongalis GJ
    Cancer Invest; 2000; 18(4):336-42. PubMed ID: 10808369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
    Kumar R; Mendelsohn J
    Anticancer Res; 1994; 14(3A):1001-8. PubMed ID: 7915505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
    Looi LM; Cheah PL; Yap SF
    Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p185HER2 signal transduction in breast cancer cells.
    Scott GK; Dodson JM; Montgomery PA; Johnson RM; Sarup JC; Wong WL; Ullrich A; Shepard HM; Benz CC
    J Biol Chem; 1991 Aug; 266(22):14300-5. PubMed ID: 1677643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.
    Kern JA; Torney L; Weiner D; Gazdar A; Shepard HM; Fendly B
    Am J Respir Cell Mol Biol; 1993 Oct; 9(4):448-54. PubMed ID: 8104437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage.
    Pupa SM; Ménard S; Morelli D; Pozzi B; De Palo G; Colnaghi MI
    Oncogene; 1993 Nov; 8(11):2917-23. PubMed ID: 8105438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines.
    Kopreski MS; Lipton A; Harvey HA; Kumar R
    Anticancer Res; 1996; 16(1):433-6. PubMed ID: 8615649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
    Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
    Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.